[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Liquidia Technologies, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":129},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,76,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100651329","phase-4-a-study-of-inhaled-treprostinil-liq861-in-adults-with-pulmonary-arterial-hypertension-transitioning-from-oral-selexipag-100651329",false,"NCT07759804","A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag","An Open-label Study to Evaluate the Safety and Tolerability of LIQ861 in Participants With WHO Group 1 PAH Transitioning From Oral Selexipag to Inhaled Treprostinil","Inclusion Criteria:\n\n* Male or female 18 to 80 years of age\n* Documented findings on right heart catheterization consistent with a diagnosis of WHO Group 1 pulmonary arterial hypertension of one of the following subtypes: idiopathic PAH; heritable PAH; drug- or toxin-induced PAH; PAH associated with connective tissue disease; or PAH associated with simple congenital systemic-to-pulmonary shunts repaired at least 1 year previously\n* Receiving selexipag at any dose between 200 and 1600 mcg twice daily for at least 90 days, and willing and able to transition from selexipag to LIQ861 due to unsatisfactory clinical response or tolerability issues\n* May be receiving up to 2 additional approved non-prostacyclin oral PAH therapies at a stable dose and regimen, planned to continue unchanged for the duration of the study\n* New York Heart Association Functional Class II or III\n* Able to demonstrate correct use of the dry powder inhaler\n\nExclusion Criteria:\n\n* Pulmonary hypertension in WHO Group 2, 3, 4, or 5, or a WHO Group 1 subtype not listed in the inclusion criteria\n* Clinically significant left-sided heart disease by echocardiography, including left ventricular ejection fraction ≤ 45%, left atrial volume index \\> 48 mL\u002Fm², or hemodynamically significant valvular disease\n* Symptomatic coronary artery disease within the previous 6 months\n* Prior atrial septostomy","ALL","18 Years","80 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a medicine breathed into the lungs.\n\nEveryone who takes part will receive LIQ861. On the first study day, participants will stop taking selexipag and begin taking LIQ861 four times a day using a small handheld dry powder inhaler. The dose may be increased over time based on how well it is tolerated. Participants will take LIQ861 for 16 weeks.\n\nThe study will also look at whether switching to LIQ861 affects walking distance, a blood marker of heart strain, and symptoms reported by participants.",[27],"Pulmonary Arterial Hypertension (PAH)",[29,30,31,32,33],"pulmonary arterial hypertension","PAH","selexipag","prostacyclin","dry powder inhaler","NOT_YET_RECRUITING","2026-08-07",{"date":37,"type":38},"2026-08-12","ACTUAL",{"date":40,"type":21},"2026-09",{"date":42,"type":21},"2027-06",{"name":44,"class":45},"Liquidia Technologies, Inc.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100650413","phase-2-a-study-of-liq861-inhaled-treprostinil-in-adults-with-systemic-sclerosis-who-have-symptomatic-raynauds-phenomenon-attacks-100650413","NCT07748000","A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks","A Phase 2a Randomized, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of LIQ861 in Participants With Systemic Sclerosis Experiencing Symptomatic Raynaud's Phenomenon Attacks \u002F RE-WARM","RE-WARM","Inclusion Criteria:\n\n* Male or female ≥18 years of age\n* Classification of SSc per the 2013 ACR\u002FEULAR criteria.\n* Diagnosis or history of Raynaud's phenomenon\n* Minimum of 12 (maximum 100) symptomatic RP attacks documented in the ePRO diary over ≥4 separate days\n\nExclusion Criteria:\n\n* ≥3 digital ulcers at screening; a new digital ulcer between screening and randomization; gangrene or amputation within 6 months; digital ulcer infection within 3 months.\n* History of cervical\u002Fdigital sympathectomy or hand botulinum toxin injections within 90 days (or planned during the study).\n* Clinically significant bleeding risk, coagulation disorder, or platelet count \\\u003C100 x 10\\^9\u002FL.\n* Known WHO Group 1-5 pulmonary hypertension; significant obstructive (FEV1 \\\u003C65%) or restrictive (FVC \\\u003C60%) lung disease; need for supplemental oxygen; severe asthma.\n* Severe uncontrolled hypertension (SBP ≥160 and\u002For DBP \\>100 mmHg) or severe hypotension (SBP \\\u003C85 mmHg).\n* Any parenteral, inhaled, or oral prostacyclin or prostacyclin receptor agonist within 12 weeks of screening; initiation\u002Fdose change of vasodilators within 4 weeks of screening; non-topical CYP2C8 inhibitors\u002Finducers (unless discontinued for \\>5 half-lives before randomization).",{"count":56,"type":21},75,[58],"PHASE2","Systemic sclerosis (SSc) is a rare autoimmune disease in which many patients experience Raynaud's phenomenon (RP) - painful episodes where commonly fingers or toes change color and become painful, numb, or tingly, usually triggered by cold or stress. This open-label study is testing an inhaled powder form of treprostinil (LIQ861) to find out which doses can be taken safely and comfortably by adults with SSc who have frequent symptomatic RP attacks. About 75 adults will be randomly assigned (2 to 1) to either a dose-titration group or a fixed low-dose group. The study also explores whether treatment reduces the number, severity, and impact of RP attacks. The main goal is to identify tolerated dose(s).",[61],"Raynaud's Phenomenon Secondary to Systemic Sclerosis",[63,64,65,66,67,33,68],"systemic sclerosis","Raynaud's phenomenon","Digital ischemia","treprostinil","prostacyclin analog","vasodilator","2026-08-05",{"date":35,"type":38},{"date":72,"type":21},"2026-10-26",{"date":74,"type":21},"2027-03",{"name":44,"class":45},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100614904","phase-3-a-phase-3-study-to-evaluate-the-safety-and-efficacy-l606-in-participants-with-ph-ild-100614904","NCT07285655","A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD","A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)","Re-Spire","Inclusion Criteria:\n\n* Participant is between 18 years to 80 years old.\n* Has a confirmed diagnosis of ILD based on High Resolution Computed Tomography (HRCT) chest imaging.\n* Evidence of PH as demonstrated from Right Heart Catheterization (RHC) with the following hemodynamic parameters:\n* Pulmonary vascular resistance (PVR) ≥ 320 dynes.sec\u002Fcm5 (i.e. 4 Woods Units (WU)), and\n* Mean Pulmonary Artery Pressure (mPAP) of ≥ 25 mmHg, and\n* \\- Pulmonary capillary wedge pressure (PCWP) or Left-Ventricular End Diastolic Pressure (LVEDP) of ≤ 15 mmHg.\n* FEV1\u002FFVC (ratio) \\> 0.70.\n* 6-minute walk distance ≥ 150 meters\n\nExclusion Criteria:\n\n* PH in the updated WHO Classification Groups 1, 2, 4, or 5.\n* Has evidence of clinically significant left-sided heart disease as defined by echocardiography.\n* Participants with history of persistent\u002Fpermanent or uncontrolled atrial fibrillation.\n* Participants with severe obstructive sleep apnea.\n* Has experienced exacerbation of underlying lung disease or active respiratory infection requiring antibiotics.\n* Initiation of pulmonary rehabilitation.\n\nNote: Other protocol defined inclusion\u002Fexclusion criteria may apply.",{"count":85,"type":21},344,[87],"PHASE3","The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the \"six-minute walk test\"). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this is by looking at the distance people walk at different times in the study on different doses of L606. Throughout the study, doctors will also closely monitor for any side effects people have to make sure L606 is safe. People who decide to join this study will be randomly (like tossing a coin) placed into one of two groups: one group will get L606 and the other group will get a placebo, which will look like L606 but will not contain any active medicine. At the end of the initial blinded portion of the study, study participants may have the opportunity to enroll in an open-label extension portion of the study where all participants will receive L606.",[90],"Pulmonary Hypertension Due to Lung Disease (Disorder)",[92,93],"pulmonary hypertension","interstitial lung disease","RECRUITING","2026-06-25",{"date":97,"type":38},"2026-06-29",{"date":99,"type":38},"2026-04-23",{"date":101,"type":21},"2031-12",{"name":44,"class":45},16,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":112,"targetDuration":114,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100526015","an-open-label-prospective-multicenter-study-to-evaluate-safety-and-tolerability-of-dry-powder-inhaled-treprostinil-in-ph-100526015","NCT06129240","An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH","An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension","ASCENT","Cohort A Key Inclusion Criteria:\n\n1. Males or Females between 18 years to 80 years of age.\n2. Has a confirmed diagnosis of WHO Group 3 PH-ILD based on CT chest imaging performed, which demonstrates evidence of diffuse parenchymal lung disease and FEV1\u002FFVC (absolute values) ≥ 70% and are required to have evidence of pulmonary hypertension (PH) as demonstrated from right heart catheterization (RHC) with the following hemodynamic parameters.\n\n   1. i) Pulmonary vascular resistance (PVR) ≥ 3 Wood Units (WU) and ii) Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and iii) A mean pulmonary arterial pressure (mPAP) of ≥ 30 mmHg.\n\n      OR\n   2. An exploratory subset of subjects with ILD: i) Pulmonary vascular resistance (PVR) ≥ 3 Wood Units (WU) and ii) Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and iii) A mean pulmonary arterial pressure (mPAP) of ≥ 21 mmHg.\n3. 6-minute walk distance of ≥ 125 meters\n\nCohort A Key Exclusion Criteria:\n\nA Subject is not eligible for inclusion in the study if any of the following criteria apply:\n\n1. PH in the Updated WHO Classification Groups 1, 2, 4, or 5.\n2. History of hemodynamically significant left-sided heart disease.\n3. Exacerbation of underlying lung disease or active pulmonary or upper respiratory infections.\n4. Initiation of pulmonary rehabilitation.\n\nCohort B Key Inclusion Criteria\n\n1. Male or Females between 18 years to 75 years of age at Screening.\n2. Has a diagnosis of WHO Group 3 PH-ILD confirmed with CT chest imaging performed at the screening visit, which demonstrates evidence of diffuse parenchymal lung disease and FEV1\u002FFVC (absolute values) ≥70%. Subjects are required to have evidence of pulmonary hypertension (PH) as demonstrated from right heart catheterization (RHC) with the following documented parameters:\n\n   1. Pulmonary vascular resistance (PVR) ≥3 Wood Units (WU) and\n   2. Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and\n   3. A mean pulmonary arterial pressure (mPAP) of ≥ 25 mmHg\n3. Subjects must be on protocol specified dose of inhaled treprostinil QID not at treatment goal, and able to transition from their prescribed dose of inhaled Treprostinil therapy to LIQ861.\n4. 6-minute walk distance of ≥ 200 meters\n\nCohort B Key Exclusion Criteria\n\n1. PH in the Updated WHO Classification Groups 1, 2, 4, or 5.\n2. Inability to titrate inhaled treprostinil above 5 breaths (Tyvaso®) or above 16 mcg Tyvaso DPI®.\n3. History of Bronchospasm with Tyvaso or Tyvaso DPI.\n4. History of persistent moderate asthma or severe asthma.\n5. History of hemodynamically significant left-sided heart disease.\n6. Exacerbation of underlying lung disease or active pulmonary or upper respiratory infections.",{"count":113,"type":21},80,"52 Weeks","OBSERVATIONAL","Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \\& 3 PH.",[118,119],"Pulmonary Hypertension","Interstitial Lung Disease","2026-06-24",{"date":122,"type":38},"2026-06-26",{"date":124,"type":38},"2023-12-28",{"date":126,"type":21},"2028-02-08",{"name":44,"class":45},23,""]